CRLF2
CRLF2 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||
Identifiers | |||||||||||||||
Aliases | CRLF2, CRL2, CRLF2Y, TSLPR, cytokine receptor-like factor 2 | ||||||||||||||
External IDs | MGI: 1889506 HomoloGene: 49476 GeneCards: CRLF2 | ||||||||||||||
Orthologs | |||||||||||||||
Species | Human | Mouse | |||||||||||||
Entrez | |||||||||||||||
Ensembl | |||||||||||||||
UniProt | |||||||||||||||
RefSeq (mRNA) | |||||||||||||||
RefSeq (protein) | |||||||||||||||
Location (UCSC) | Chr X: 1.19 – 1.21 Mb | Chr 5: 109.55 – 109.56 Mb | |||||||||||||
PubMed search | [1] | [2] | |||||||||||||
Wikidata |
View/Edit Human | View/Edit Mouse |
Cytokine receptor-like factor 2 is a protein that in humans is encoded by the CRLF2 gene.[3][4][5]
Cytokine signals are mediated through specific receptor complexes, the components of which are mostly members of the type I cytokine receptor family. Type I cytokine receptors share conserved structural features in their extracellular domain. Receptor complexes are typically heterodimeric, consisting of alpha chains, which provide ligand specificity, and beta (or gamma) chains, which are required for the formation of high-affinity binding sites and signal transduction.[supplied by OMIM][5]
References
- ↑ "Human PubMed Reference:".
- ↑ "Mouse PubMed Reference:".
- ↑ Zhang W, Wang J, Wang Q, Chen G, Zhang J, Chen T, Wan T, Zhang Y, Cao X (Mar 2001). "Identification of a novel type I cytokine receptor CRL2 preferentially expressed by human dendritic cells and activated monocytes". Biochem Biophys Res Commun. 281 (4): 878–83. doi:10.1006/bbrc.2001.4432. PMID 11237741.
- ↑ Tonozuka Y, Fujio K, Sugiyama T, Nosaka T, Hirai M, Kitamura T (Jul 2001). "Molecular cloning of a human novel type I cytokine receptor related to delta1/TSLPR". Cytogenet Cell Genet. 93 (1–2): 23–5. doi:10.1159/000056941. PMID 11474172.
- 1 2 "Entrez Gene: CRLF2 cytokine receptor-like factor 2".
Further reading
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Hiroyama T, Iwama A, Morita Y, et al. (2000). "Molecular cloning and characterization of CRLM-2, a novel type I cytokine receptor preferentially expressed in hematopoietic cells". Biochem. Biophys. Res. Commun. 272 (1): 224–9. doi:10.1006/bbrc.2000.2764. PMID 10872831.
- Reche PA, Soumelis V, Gorman DM, et al. (2001). "Human thymic stromal lymphopoietin preferentially stimulates myeloid cells". J. Immunol. 167 (1): 336–43. doi:10.4049/jimmunol.167.1.336. PMID 11418668.
- Blagoev B, Nielsen MM, Angrist M, et al. (2002). "Cloning of rat thymic stromal lymphopoietin receptor (TSLPR) and characterization of genomic structure of murine Tslpr gene". Gene. 284 (1–2): 161–8. doi:10.1016/S0378-1119(02)00380-3. PMID 11891057.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Rochman I, Watanabe N, Arima K, et al. (2007). "Cutting edge: direct action of thymic stromal lymphopoietin on activated human CD4+ T cells". J. Immunol. 178 (11): 6720–4. doi:10.4049/jimmunol.178.11.6720. PMID 17513717.
This article is issued from Wikipedia - version of the 6/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.